AdCella and Shanghai Cell Therapy Group Co Ltd launch global collaboration on groundbreaking cancer therapy

First-in-class PD1 armored MSLN CAR-T anchors “East to West” cellular immunotherapy pipeline

• AdAlta and its AdCella subsidiary have executed a Development and Collaboration Agreement (“DCA”) to co-develop Shanghai Cell Therapy Group Co Ltd (“SHcell”)’s BZDS1901 for all markets outside greater China

• BZDS1901 is a highly differentiated clinical stage, first-in-class armored CAR-T product targeting mesothelin (“MSLN”) with demonstrated complete responses in difficult to treat advanced mesothelioma patients and a low cost, scalable manufacturing process

• AdCella is financing BZDS1901 development outside greater China via third party investors and will be responsible for establishing a manufacturing platform and conducting a Phase 1 clinical trial in mesothelioma and other solid cancers in Australia

• AdCella will acquire a share of the proceeds of any commercialization event at the completion of Phase 1 clinical trials